イスラエル - 英語 - Ministry of Health

taro international ltd, israel - esomeprazole - tablets - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 40 mg tablets are indicated in adolescents from the age of 12 years for;gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis

イスラエル - 英語 - Ministry of Health

astrazeneca (israel) ltd - esomeprazole - tablets - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 40 mg tablets are indicated in adolescents from the age of 12 years for;gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis

イスラエル - 英語 - Ministry of Health

sanofi israel ltd - hydrochlorothiazide; ramipril - tablets - ramipril 2.5 mg; hydrochlorothiazide 12.5 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension.tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone or hydrochlorothiazide alone.

イスラエル - 英語 - Ministry of Health

sanofi israel ltd - hydrochlorothiazide; ramipril - tablets - ramipril 5 mg; hydrochlorothiazide 25 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension.tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone or hydrochlorothiazide alone.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

pco manufacturing - omeprazole magnesium - tablets gastro-resistant - 40 milligram

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.